Microarray analysis reveals potential mechanisms of BRMS1-mediated metastasis suppression

Clinical and Experimental Metastasis

Volumn 24, Issue 7, 2007, Pages 551-565

  Champine, Patricia J ^a   Michaelson, Jacob ^a,b   Weimer, Bart C ^a   Welch, Danny R ^c,d   DeWald, Daryll B ^a,d  

^a UTAH STATE UNIVERSITY   (United States)

^b MAX PLANCK INSTITUTE   (Germany)

^c University of Alabama at Birmingham   (United States)

^d Center for Metastasis Research   (United States)

Author keywords

Affymetrix; Breast cancer; BRMS1; Metastasis; MHC; Microarray

Indexed keywords

ANTIGEN RECOGNITION; ARTICLE; BREAST METASTASIS; CONTROLLED STUDY; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE FUNCTION; HUMAN; HUMAN CELL; IN VITRO STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; METASTASIS INHIBITION; MICROARRAY ANALYSIS; MICROENVIRONMENT; NUCLEOTIDE SEQUENCE; PROTEIN LOCALIZATION; PROTEIN SECRETION; STATISTICAL SIGNIFICANCE; UNINDEXED SEQUENCE;

BIOLOGICAL TRANSPORT; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MICROARRAY ANALYSIS; NEOPLASM METASTASIS; NEOPLASM PROTEINS; REPRODUCIBILITY OF RESULTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 34948843568     PISSN: 02620898     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10585-007-9092-8     Document Type: Article

References (40)

1. Shevde LA, Welch DR (2003) Metastasis suppressor pathways-an evolving paradigm. Cancer Lett 198:1-20
2. Steeg PS (2003) Metastasis suppressors alter the signal transduction of cancer cells. Nat Rev Cancer 3:55-63
3. Rinker-Schaeffer CW, O'Keefe JP, Welch DR, Theodorescu D (2006) Metastasis suppressor proteins: discovery, molecular mechanisms, and clinical application. Clin Cancer Res 12:3882-3889
4. Samant RS, Seraj MJ, Saunders MM, Sakamaki TS, Shevde LA, Harms JF, Leonard TO, Goldberg SF, Budgeon L, Meehan WJ, Winter CR, Christensen ND, Verderame MF, Donahue HJ, Welch DR (2000) Analysis of mechanisms underlying BRMS1 suppression of metastasis. Clin Exp Metastasis 18:683-693
5. Saunders MM, Seraj MJ, Li Z, Zhou Z, Winter CR, Welch DR, Donahue HJ (2001) Breast cancer metastatic potential correlates with a breakdown in homospecific and heterospecific gap junctional intercellular communication. Cancer Res 61:1765-1767
6. Cicek M, Fukuyama R, Welch DR, Sizemore N, Casey G (2005) Breast cancer metastasis suppressor 1 inhibits gene expression by targeting nuclear factor-kappaB activity. Cancer Res 65:3586-3595
7. DeWald DB, Torabinejad J, Samant RS, Johnston D, Erin N, Shope JC, Xie Y, Welch DR (2005) Metastasis suppression by breast cancer metastasis suppressor 1 involves reduction of phosphoinositide signaling in MDA-MB-435 breast carcinoma cells. Cancer Res 65:713-717
8. Meehan WJ, Samant RS, Hopper JE, Carrozza MJ, Shevde LA, Workman JL, Eckert KA, Verderame MF, Welch DR (2004) Breast cancer metastasis suppressor 1 (BRMS1) forms complexes with retinoblastoma-binding protein 1 (RBP1) and the mSin3 histone deacetylase complex and represses transcription. J Biol Chem 279:1562-1569
9. Ohta S, Lai EW, Pang AL, Brouwers FM, Chan WY, Eisenhofer G, de Krijger R, Ksinantova L, Breza J, Blazicek P, Kvetnansky R, Wesley RA, Pacak K (2005) Downregulation of metastasis suppressor genes in malignant pheochromocytoma. Int J Cancer 114:139-143
10. Samant RS, Debies MT, Hurst DR, Moore BP, Shevde LA, Welch DR (2006) Suppression of murine mammary carcinoma metastasis by the murine ortholog of breast cancer metastasis suppressor 1 (Brms1). Cancer Lett 235:260-265
11. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK (2001) Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 1:194-202
12. R Development Core Team (2006) R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria
13. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J, Hornik K, Hothorn T, Huber W, Iacus S, Irizarry R, Leisch F, Li C, Maechler M, Rossini AJ, Sawitzki G, Smith C, Smyth G, Tierney L, Yang JY, Zhang J (2004) Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 5:R80
14. Irizarry RA, Gautier L, Bolstad BM, Miller C with contributions from Astrand M, Cope LM, Gentleman R, Gentry J, Halling C, Huber W, MacDonald J, Rubinstein BIP, Workman C, Zhang J (2005) affy: Methods for Affymetrix Oligonucleotide Arrays. In: R package
15. Smyth GK (2005) Limma: linear models for microarray data. In: Gentleman R, Carey V, Dudoit S, Irizarry R, Huber W (ed), Bioinformatics and computational biology solutions using R and bioconductor. Springer, New York, pp 397-420
16. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, Harris MA, Hill DP, Issel-Tarver L, Kasarskis A, Lewis S, Matese JC, Richardson JE, Ringwald M, Rubin GM, Sherlock G (2000) Gene ontology: tool for the unification of biology. The gene ontology consortium. Nat Genet 25:25-29
17. Maglott D, Ostell J, Pruitt KD, Tatusova T (2005) Entrez gene: gene-centered information at NCBI. Nucleic Acids Res 33:D54-58
18. Gentleman R (2004) Using GO for statistical analyses. In: Antoch J (ed) Proceedings in computational statistics. Physica Verlag, pp 171-180
19. Lumley T, Warnes G, Bolker B (2006) Gplots: various R programming tools for plotting data. R package version 2.3.1
20. Solana R, Romero J, Alonso C, Pena J (1992) MHC class I antigen expression is inversely related with tumor malignancy and ras oncogene product (p21ras) levels in human breast tumors. Invasion Metastasis 12:210-217
21. Goepel JR, Rees RC, Rogers K, Stoddard CJ, Thomas WE, Shepherd L (1991) Loss of monomorphic and polymorphic HLA antigens in metastatic breast and colon carcinoma. Br J Cancer 64:880-883
22. Palmisano GL, Pistillo MP, Fardin P, Capanni P, Nicolo G, Salvi S, Spina B, Pasciucco G, Ferrara GB (2002) Analysis of HLA-G expression in breast cancer tissues. Hum Immunol 63:969-976
23. Dadmarz R, Sgagias MK, Rosenberg SA, Schwartzentruber DJ (1995) CD4+ T lymphocytes infiltrating human breast cancer recognise autologous tumor in an MHC-class-II restricted fashion. Cancer Immunol Immunother 40:1-9
24. Garrido F, Ruiz-Cabello F (1991) MHC expression on human tumors-its relevance for local tumor growth and metastasis. Semin Cancer Biol 2:3-10
25. Maiorana A, Cesinaro AM, Fano RA, Collina G (1995) Expression of MHC class I and class II antigens in primary breast carcinomas and synchronous nodal metastases. Clin Exp Metastasis 13:43-48
26. Sotiriadou R, Perez SA, Gritzapis AD, Sotiropoulou PA, Echner H, Heinzel S, Mamalaki A, Pawelec G, Voelter W, Baxevanis CN, Papamichail M (2001) Peptide HER2(776-788) represents a naturally processed broad MHC class II-restricted T cell epitope. Br J Cancer 85:1527-1534
27. Foss FM (2002) Immunologic mechanisms of antitumor activity. Semin Oncol 29:5-11
28. Remedi MM, Bonacci G, Vides MA, Donadio AC (2003) Immune control of tumors by antigen presentation improvement. Tumour Biol 24:228-235
29. Fan P, Wang S, Liu X, Zhen L, Wu Z (2002) Major histocompatibility complex class II antigen and costimulatory molecule expression on the surface of breast cancer cells. Zhonghua Zhong Liu Za Zhi 24:327-330
30. Shi B, Vinyals A, Alia P, Broceno C, Chen F, Adrover M, Gelpi C, Price JE, Fabra A (2006) Differential expression of MHC class II molecules in highly metastatic breast cancer cells is mediated by the regulation of the CIITA transcription Implication of CIITA in tumor and metastasis development. Int J Biochem Cell Biol 38:544-562
31. Gorelik E, Kim M, Duty L, Henion T, Galili U (1993) Control of metastatic properties of BL6 melanoma cells by H-2Kb gene: immunological and nonimmunological mechanisms. Clin Exp Metastasis 11:439-452
32. Walter W, Lingnau K, Schmitt E, Loos M, Maeurer MJ (2000) MHC class II antigen presentation pathway in murine tumours: tumour evasion from immunosurveillance? Br J Cancer 83:1192-1201
33. Jordens I, Marsman M, Kuijl C, Neefjes J (2005) Rab proteins, connecting transport and vesicle fusion. Traffic 6:1070-1077
34. Grosshans BL, Ortiz D, Novick P (2006) Rabs and their effectors: achieving specificity in membrane traffic. Proc Natl Acad Sci USA 103:11821-11827
35. Sannerud R, Marie M, Nizak C, Dale HA, Pernet-Gallay K, Perez F, Goud B, Saraste J (2006) Rab1 defines a novel pathway connecting the pre-Golgi intermediate compartment with the cell periphery. Mol Biol Cell 17:1514-1526
36. Kuroda TS, Fukuda M, Ariga H, Mikoshiba K (2002) The Slp homology domain of synaptotagmin-like proteins 1-4 and Slac2 functions as a novel Rab27A binding domain. J Biol Chem 277:9212-9218
37. Liu H, Liu ZQ, Chen CX, Magill S, Jiang Y, Liu YJ (2006) Inhibitory regulation of EGF receptor degradation by sorting nexin 5. Biochem Biophys Res Commun 342:537-546
38. Merino-Trigo A, Kerr MC, Houghton F, Lindberg A, Mitchell C, Teasdale RD, Gleeson PA (2004) Sorting nexin 5 is localized to a subdomain of the early endosomes and is recruited to the plasma membrane following EGF stimulation. J Cell Sci 117:6413-6424
39. Bruns JR, Ellis MA, Jeromin A, Weisz OA (2002) Multiple roles for phosphatidylinositol 4-kinase in biosynthetic transport in polarized Madin-Darby canine kidney cells. J Biol Chem 277:2012-2018
40. Wang YJ, Wang J, Sun HQ, Martinez M, Sun YX, Macia E, Kirchhausen T, Albanesi JP, Roth MG, Yin HL (2003) Phosphatidylinositol 4 phosphate regulates targeting of clathrin adaptor AP-1 complexes to the Golgi. Cell 114:299-310